EMB-01
EMB-01：Achieving Anti-Tumor Activity through Novel Mechanisms
Novel Mechanisms
Dual blockade
Overcome resistance caused by mutations of the EGFR
Internalization & Co-degradation
Tetravalent binding to two types of tumor cell surface targets
Novel Mechanism and Preclinical Validation
Validation of the Mechanism
Internalization & co-degradation has been demonstrated in EMB-01 using Confocal Microscopy
Early Activity in Preclinical Models
EMB-01 showed superior anti-tumor activity vs. EGFR or cMET antibodies, and sustained tumor suppression even after completion of dosing
Addressing Major Unmet Medical Need with Potential Large Market
Unmet Clinical Needs
Large Potential Market
Large Potential Market
>50%
Asian NSCLC patients with EGFR mutation
~25%
of resistance to 3rd gen TKI
osimertinib can be driven by MET
osimertinib can be driven by MET
TKI resistant patients: Increasing number even following treatment with 3rd generation EGFR TKIs
Efficacy in multiple cancer types, including lung, liver, gastrointestinal etc.
Top Clinical PI For Novel Drug
Leading Phase I/II trial in US and China
Leading Phase I/II trial in US and China
Prof. Yilong Wu
Investigator of global TKI and checkpoint inhibitor trials including PD1/L1 in lung cancer
“China Contributor” to global lung cancer research
IASLC Paul Bunn Award, Member of American College of Surgeons
Former Chief of Chinese Society of Clinic Oncology (CSCO)
